Randomized, double-blind, crossover, placebo-controlled comparison of propranolol and betaxolol in the treatment of neuroleptic-induced akathisia.

Abstract

OBJECTIVE:

Beta-blocking agents, particularly propranolol, are considered effective in the treatment of neuroleptic-induced akathisia, but considerable controversy exists about the involved receptor subtype(s). The authors conducted a randomized, controlled trial comparing the effects of propranolol and betaxolol to determine whether central beta 1-adrenoceptor blockade is sufficient to correct neuroleptic-induced akathisia.

METHOD:

The subjects were 19 patients whose neuroleptic-induced akathisia responded to 20 mg/day of propranolol and subsequently reemerged during a placebo washout period. They were randomly assigned to propranolol (20 or 40 mg/day) or betaxolol (10 or 20 mg/day) and, after another placebo period, were switched to the second beta blocker.

RESULTS:

There was no significant difference in the antiakathisia effects of propranolol and betaxolol.

CONCLUSIONS:

The lack of difference between propranolol and betaxolol suggests that beta 1-adrenoceptor blockade is sufficient to improve neuroleptic-induced akathisia. The results of this explanatory study need therapeutic confirmation.

• Authors: J P Dumon, J Catteau, F Lanvin, B A Dupuis
• Journal: The American journal of psychiatry (Am J Psychiatry) Vol. 149 Issue 5 Pg. 647-50 (May 1992) ISSN: 0002-953X [Print] United States
• PMID: 1349458 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)

Chemical References

• Antipsychotic Agents
• Placebos
• Propranolol
• Betaxolol

Topics

• Adult
• Akathisia, Drug-Induced
• Antipsychotic Agents (adverse effects)
• Betaxolol (therapeutic use)
• Double-Blind Method
• Humans
• Middle Aged
• Placebos
• Propranolol (therapeutic use)
• Psychomotor Agitation (drug therapy)